# MINTS

> MINTS is a VC fund in Ann Arbor backing Health Care, Medical and Software. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Ann Arbor, United States
- Total investments: 11
- Last investment: Jul 2024
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.cfe.umich.edu/resources/mints

MINTS is a VC fund in Ann Arbor focused on Health Care and Medical. MINTS initiative is a $25m venture fund for the University of Michigan to leverage commercialization efforts by the Office of Technology Transfer (OTT) for investment purposes while demonstrating support for U-M start-ups. The program will be managed by the University’s Investment office, with the support of OTT and the General Counsel’s Office, aspart of the University’s long-term portfolio of investments.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 45% |
| Medical | 3 | 27% |
| Software | 2 | 18% |
| Therapeutics | 2 | 18% |
| Biotechnology | 2 | 18% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 27% |
| Seed | 2 | 18% |
| Series B | 2 | 18% |
| Series C | 1 | 9% |
| Funding Round | 1 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 45% |
| Belgium | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Confo Therapeutics | Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M | Series B | Jul 26, 2024 |  |
| ONL Therapeutics | ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $15M | Series C | Mar 08, 2023 |  |
| CubeWorks | CubeWorks’ mission is to accelerate the future of IoT and build a world connected by ubiquitous sensor technology through millimeter-scale smart sensing solutions. In 2013, following a decade of research on ultra-low-power circuitry at the University of Michigan, CubeWorks was founded to advance the next generation of IoT sensors. Today, with thedevelopment of the CubiSens™ Platform, CubeWorks brings to market a portfolio of ultra-small wireless smart sensors. These sensors offer limitless potential across a broad range of applications and provide access to mission-critical information exactly when and where it is needed. | $2.4M | Seed | Jun 01, 2022 |  |
| FlexDex | FlexDex is a minimally invasive surgery medical device technology that provides high dexterity. Its platform technology translates the surgeon’s hand, wrist, and arm movements from outside the patient into corresponding movements of an end-effector inside the patient’s body.The company was founded in 2010 and is headquartered in Brighton,Michigan. | $13M | Venture - Series Unknown | Aug 24, 2021 |  |
| ONL Therapeutics | ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $46.9M | Series B | Dec 22, 2020 |  |
| Ripple Science | Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. | $2.5M |  | Jan 07, 2020 |  |
| Ripple Science | Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. | $2.5M | Seed | Jan 07, 2020 |  |
| Confo Therapeutics | Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $33.6M | Series A | May 07, 2019 |  |
| Fifth Eye | Fifth Eye develops a medical device software that provides a view of a patient’s evolving hemodynamic trajectory. It enables proactive patient care to improve outcomes, avoid adverse events, shorten lengths of stay, and reduce costs. | $11.5M | Series A | Apr 01, 2019 |  |
| Ripple Science | Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. | $1.8M | Seed | Jun 15, 2018 |  |

10 of 11 investments shown.

## Co-investors
- [Biosciences Research and Commercialization Center (BRCC)](https://shizune.co/investors/profile/biosciences-research-and-commercialization-center-brcc) — VC Fund, 3 deals together
- [Capital Community Angel Investors](https://shizune.co/investors/profile/capital-community-angels-investors) — VC Fund, 3 deals together
- [ExSight Ventures](https://shizune.co/investors/profile/exsight-ventures) — VC Fund, 3 deals together
- [Invest Michigan](https://shizune.co/investors/profile/invest-michigan) — VC Fund, 3 deals together
- [Almeda Ventures](https://shizune.co/investors/profile/almeda-ventures) — VC Fund, 2 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does MINTS invest in?

MINTS invests primarily in Health Care, Medical and Software startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did MINTS last invest?

The most recent investment recorded for MINTS closed in Jul 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co